Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479972 | 0.86 | KDR (0.45) | KDRCDK4PKMALDH1A1 | |
| SCHEMBL4478445 | 0.80 | DYRK1A (0.43) | CDK4PTGS2DYRK1AALDH1A1MAPK1 | |
| SCHEMBL4479149 | 0.79 | TDP1 (0.42) | KDRCDK4DYRK1AALDH1A1 | |
| SCHEMBL4479153 | 0.79 | TDP1 (0.42) | KDRCDK4DYRK1AALDH1A1 | |
| SCHEMBL14754845 | 0.76 | KDR (0.45) | KDRCDK4PTGS2PTGS1DYRK1A | |
| SCHEMBL4480362 | 0.75 | GSK3B (0.43) | KDRCDK4PTGS2DYRK1AALDH1A1 | |
| SCHEMBL4471819 | 0.75 | PTGS2 (0.52) | KDRPKMPTGS2PTGS1 | |
| SCHEMBL5847756 | 0.74 | MIF (0.48) | ALOX15ALDH1A1MAPK1EGFR | |
| SCHEMBL4471815 | 0.71 | ALDH1A1 (0.39) | CDK4ALDH1A1 | |
| SCHEMBL20669578 | 0.70 | DYRK1A (0.43) | CDK4PKMPTGS2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | SMITHKLINE BEECHAM CORPORATION | 2005-04-28 | — | — | US | disclosed |
| EP-1463730-A1 | PYRAZOLOPARIDAZINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003051886-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090507-A1 | Pyrazolopyridazine derivatves | CDK4, CDK3, CDK8 | KDR 2097/4885CDK4 1/4885PKM 926/4885 |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | KDR 4710/4885CDK4 218/4885PKM 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.